NervGen Pharma Corp. Common stock
NGEN
NASDAQ·Healthcare·Biotechnology·Mkt cap $191.5M
$2.33
▲ +0.43%
P/E
-3.84
Mkt Cap
$191.5M
52-Wk Range
$1.58–$6.30
52-Week Range
$1.58 - $6.30
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 45.4% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary nerve repair technology platform
- Focused expertise in removing inhibitory barriers to nervous system regeneration
- Strong intellectual property portfolio protecting key innovations
- Strategic partnerships with leading research institutions
Bear Case
1 risk
- Low volatility (beta 0.7).
Growth
Stable outlook
Advancement of clinical trial programs toward regulatory approval
Value
Deep value opportunity - significant discount to sector peers
Momentum
Hot
+28.0% over 3m
Quality
Loss-making
Below average quality
Dividend
None
No dividend
Smart-money signal
Who's buying NGEN right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 12, 2026
AUG 13, 2026
Reported EPS of -$0.37 vs -$0.06 consensus (-510.8% surprise).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-510.8%
Revenue trend · last 8Q
—
—
—
—
—
—
—
—
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$0
$0
$0
$0
$0
$0
$0
$0
Margins · last 8Q
No margin history available.
Wall Street consensus
1 analyst · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: TD Cowen · Jun 11, 2026
vs Industry
How NGEN stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.